• 18 years of age and above at the signing of informed consent

• Had a positive laboratory or home test for COVID19 within one year prior to signing of informed consent, with subsequent symptoms meeting criteria for PASC.

• Subjective Cognitive impairment associated with PASC

• Cognitive symptoms will be formally assessed at a pre-enrollment visit using the PROMIS Cognitive Function Questionnaire (CGQ) and the PROMIS Cognitive Abilities subset (CAS), which are validated patient-reported measures of subjective cognitive functioning. Potential participants must have a cumulative score less than 60 (indicating at least mild subjective cognitive dysfunction) to be eligible.

• Is willing and able to comply with study visits and study-related procedures/assessments.

• Is able to provide informed consent to participate in the study 5.

• Is not currently taking a medication with adverse interactions with amantadine. (Table 2)

• If the participant is of child bearing potential, , is not pregnant at enrollment based on negative urine pregnancy test.

• If the participant is of child-bearing potential, is consistently using one or more forms of prescribed birth control, such as an oral contraceptive, intrauterine device or a long-acting reversible contraceptive.

⁃ Is not breastfeeding.

⁃ Is willing to abstain from alcohol use for the duration of the study.

⁃ Endorses self-reported cognitive impairment on the PROMIS CF\[40\].

⁃ Does not have any other contraindications to amantadine use as noted in section 6 below or as identified by the study clinician investigators.